Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Short-term Investments (2016 - 2022)

Catalyst Pharmaceuticals filings provide 12 years of Short-term Investments readings, the most recent being $9.9 million for Q2 2022.

  • On a quarterly basis, Short-term Investments fell 50.57% to $9.9 million in Q2 2022 year-over-year; TTM through Jun 2022 was $9.9 million, a 50.57% decrease, with the full-year FY2021 number at $19.8 million, up 97.4% from a year prior.
  • Short-term Investments hit $9.9 million in Q2 2022 for Catalyst Pharmaceuticals, down from $19.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $58.5 million in Q2 2018 to a low of $5.0 million in Q4 2019.
  • Median Short-term Investments over the past 5 years was $20.0 million (2021), compared with a mean of $26.8 million.
  • Biggest five-year swings in Short-term Investments: soared 120.44% in 2018 and later plummeted 86.44% in 2019.
  • Catalyst Pharmaceuticals' Short-term Investments stood at $36.9 million in 2018, then plummeted by 86.44% to $5.0 million in 2019, then soared by 100.54% to $10.0 million in 2020, then skyrocketed by 97.4% to $19.8 million in 2021, then tumbled by 50.17% to $9.9 million in 2022.
  • The last three reported values for Short-term Investments were $9.9 million (Q2 2022), $19.4 million (Q1 2022), and $19.8 million (Q4 2021) per Business Quant data.